Mylan Ireland Limited has entered into an agreement to acquire the U.S. rights to Aspen Global's Arixtra Injection.
Arixtra is indicated for the prophylaxis of deep vein thrombosis.
Mylan will pay $225 million to acquire the rights for commercialization, marketing and intellectual property. Another $75 million is contingent upon satisfaction of certain conditions.
More articles on acquisitions:
3 recent hospital transactions and partnerships
J&J seeks buyer for medical device business
Covidien acquires medical device firm Sapheon